Insiders Purchase Shares of VHT ETF Holdings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 03 2025
0mins
Should l Buy VRTX?
Source: NASDAQ.COM
Insider Buying in Vanguard Health Care ETF: 18.1% of the weighted holdings in the Vanguard Health Care ETF (VHT) have seen insider buying in the past six months.
Eli Lilly's Insider Activity: Eli Lilly (LLY), the largest holding in VHT at 13.99%, has had 8 directors and officers purchase shares recently, totaling $2,565,346,919 in holdings.
Vertex Pharmaceuticals' Insider Activity: Vertex Pharmaceuticals (VRTX), the 16th largest holding in VHT, has seen 2 directors and officers file Form 4s indicating recent purchases, with holdings worth $328,800,515.
Disclaimer on Views: The opinions expressed in the article are those of the author and do not necessarily reflect the views of Nasdaq, Inc.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VRTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VRTX
Wall Street analysts forecast VRTX stock price to rise
22 Analyst Rating
17 Buy
5 Hold
0 Sell
Strong Buy
Current: 469.270
Low
414.00
Averages
515.88
High
604.00
Current: 469.270
Low
414.00
Averages
515.88
High
604.00
About VRTX
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vertex Pharmaceuticals Maintains Leadership in Cystic Fibrosis Treatment
- Market Leadership: Vertex Pharmaceuticals is the global leader in cystic fibrosis (CF) treatment, with its drugs capable of addressing approximately 90% of CF gene mutations, significantly improving patient quality of life and extending lifespans, ensuring sustained growth in this sector.
- New Drug Approvals: In recent years, Vertex has successfully gained approval for a gene editing treatment for blood disorders and a pain management drug, with expectations that these non-CF products will contribute over $500 million to revenue this year, further driving overall revenue growth.
- Financial Outlook: Vertex anticipates total revenue of up to $13.1 billion for 2023, reflecting strong financial performance underpinned by a diversified product line and stable demand, enhancing investor confidence in its long-term growth prospects.
- Investment Strategy: Although Vertex was not included in The Motley Fool Stock Advisor's top stock picks, it remains a stable biotech company considered worthy of holding during economic fluctuations, making it suitable for inclusion in a diversified investment portfolio.
See More
CRISPR Therapeutics Shows Long-Term Investment Potential
- Sales Growth Outlook: Vertex Pharmaceuticals reported higher expected sales for Casgevy in 2025 during its fourth-quarter earnings, indicating profitability primarily from cystic fibrosis treatments, although its stock price moderated shortly after the report.
- Market Potential for CRISPR: As the developer of Casgevy, CRISPR Therapeutics stands to benefit from increased sales, and with five other candidates in clinical trials, it demonstrates strong R&D capabilities in gene editing with larger potential patient pools.
- Financial Status Review: Although CRISPR Therapeutics is not yet profitable and has seen a 64% stock price decline over the past five years, it holds over $1.9 billion in cash, allowing for increased investment in pipeline candidates if Casgevy sales grow as expected.
- High-Risk, High-Reward: CRISPR Therapeutics is viewed as a high-risk, high-reward investment; despite current losses, its potential for functional cures and existing manufacturing infrastructure make it an attractive acquisition target, with its low price presenting a buying opportunity for investors.
See More
CRISPR Therapeutics Sees Stock Increase Following Earnings Report Amid Promising Pipeline Developments
Stock Performance: CRISPR Therapeutics' stock rose over 12% following the announcement of its Q4 2025 earnings, despite reporting a larger net loss and lower-than-expected revenue.
Long-Term Growth Potential: The company is in the early stages of its growth phase, with expectations for significant payoffs in the coming years as it advances its gene-editing technology.
Recent FDA Approval: CRISPR received FDA approval for its flagship gene therapy, CASGevy, which targets sickle cell disease, marking a significant milestone for the company.
Investment Outlook: While the stock has seen volatility, it may be a suitable long-term investment for those willing to wait for potential significant gains, despite current operational losses and challenges in revenue recognition.
See More
CGUS Stock Performance Analysis and ETF Dynamics
- Price Fluctuation Analysis: CGUS's 52-week low is $28.95 and high is $41.38, with the latest trade at $40.83, indicating price volatility near the high point, which may influence investor buying decisions.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable insights for investors, helping to assess price trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding focuses on those experiencing notable inflows (new units created) or outflows (old units destroyed), assessing their impact on underlying assets and market sentiment.
See More
Vertex Pharmaceuticals Sustains Innovation and Growth Amid Market Challenges
- Market Leadership: Vertex Pharmaceuticals holds a global leadership position in cystic fibrosis (CF) treatment, with its drugs significantly improving patient quality of life, which is expected to drive stable growth over the next decade.
- Revenue Growth Outlook: The company anticipates that non-CF products like the gene editing treatment Casgevy and pain drug Journavx will contribute over $500 million to revenue this year, pushing total revenue guidance to $13.1 billion, reflecting strong market demand and product diversification.
- Intellectual Property Strength: Vertex's robust intellectual property portfolio supports its leadership in CF, ensuring competitive advantage for its products over the next decade, thereby providing investors with stable return expectations.
- Investment Strategy Recommendation: Investors are advised to hold Vertex stock within a diversified portfolio, leveraging its potential as a “compounder” to mitigate risks associated with market fluctuations and secure long-term gains.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market sentiment.
- Investor Focus: When considering buying Micron Technology (MU) stock, analysts' opinions are particularly crucial, and investors should pay attention to these rating changes to make informed investment choices.
- Source of Updates: Comprehensive information on analyst rating changes, including upgrades and downgrades, can be found on our analyst ratings page, providing a thorough market insight.
- Market Impact: Adjustments in analysts' ratings not only affect the performance of individual stocks but may also create fluctuations in overall market sentiment, prompting investors to closely monitor these changes to seize investment opportunities.
See More
Vertex Pharmaceuticals Maintains Leadership in Cystic Fibrosis Treatment
- Market Leadership: Vertex Pharmaceuticals is the global leader in cystic fibrosis (CF) treatment, with its drugs capable of addressing approximately 90% of CF gene mutations, significantly improving patient quality of life and extending lifespans, ensuring sustained growth in this sector.
- New Drug Approvals: In recent years, Vertex has successfully gained approval for a gene editing treatment for blood disorders and a pain management drug, with expectations that these non-CF products will contribute over $500 million to revenue this year, further driving overall revenue growth.
- Financial Outlook: Vertex anticipates total revenue of up to $13.1 billion for 2023, reflecting strong financial performance underpinned by a diversified product line and stable demand, enhancing investor confidence in its long-term growth prospects.
- Investment Strategy: Although Vertex was not included in The Motley Fool Stock Advisor's top stock picks, it remains a stable biotech company considered worthy of holding during economic fluctuations, making it suitable for inclusion in a diversified investment portfolio.
See More
CRISPR Therapeutics Shows Long-Term Investment Potential
- Sales Growth Outlook: Vertex Pharmaceuticals reported higher expected sales for Casgevy in 2025 during its fourth-quarter earnings, indicating profitability primarily from cystic fibrosis treatments, although its stock price moderated shortly after the report.
- Market Potential for CRISPR: As the developer of Casgevy, CRISPR Therapeutics stands to benefit from increased sales, and with five other candidates in clinical trials, it demonstrates strong R&D capabilities in gene editing with larger potential patient pools.
- Financial Status Review: Although CRISPR Therapeutics is not yet profitable and has seen a 64% stock price decline over the past five years, it holds over $1.9 billion in cash, allowing for increased investment in pipeline candidates if Casgevy sales grow as expected.
- High-Risk, High-Reward: CRISPR Therapeutics is viewed as a high-risk, high-reward investment; despite current losses, its potential for functional cures and existing manufacturing infrastructure make it an attractive acquisition target, with its low price presenting a buying opportunity for investors.
See More
CRISPR Therapeutics Sees Stock Increase Following Earnings Report Amid Promising Pipeline Developments
Stock Performance: CRISPR Therapeutics' stock rose over 12% following the announcement of its Q4 2025 earnings, despite reporting a larger net loss and lower-than-expected revenue.
Long-Term Growth Potential: The company is in the early stages of its growth phase, with expectations for significant payoffs in the coming years as it advances its gene-editing technology.
Recent FDA Approval: CRISPR received FDA approval for its flagship gene therapy, CASGevy, which targets sickle cell disease, marking a significant milestone for the company.
Investment Outlook: While the stock has seen volatility, it may be a suitable long-term investment for those willing to wait for potential significant gains, despite current operational losses and challenges in revenue recognition.
See More
CGUS Stock Performance Analysis and ETF Dynamics
- Price Fluctuation Analysis: CGUS's 52-week low is $28.95 and high is $41.38, with the latest trade at $40.83, indicating price volatility near the high point, which may influence investor buying decisions.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable insights for investors, helping to assess price trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding focuses on those experiencing notable inflows (new units created) or outflows (old units destroyed), assessing their impact on underlying assets and market sentiment.
See More
Vertex Pharmaceuticals Sustains Innovation and Growth Amid Market Challenges
- Market Leadership: Vertex Pharmaceuticals holds a global leadership position in cystic fibrosis (CF) treatment, with its drugs significantly improving patient quality of life, which is expected to drive stable growth over the next decade.
- Revenue Growth Outlook: The company anticipates that non-CF products like the gene editing treatment Casgevy and pain drug Journavx will contribute over $500 million to revenue this year, pushing total revenue guidance to $13.1 billion, reflecting strong market demand and product diversification.
- Intellectual Property Strength: Vertex's robust intellectual property portfolio supports its leadership in CF, ensuring competitive advantage for its products over the next decade, thereby providing investors with stable return expectations.
- Investment Strategy Recommendation: Investors are advised to hold Vertex stock within a diversified portfolio, leveraging its potential as a “compounder” to mitigate risks associated with market fluctuations and secure long-term gains.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market sentiment.
- Investor Focus: When considering buying Micron Technology (MU) stock, analysts' opinions are particularly crucial, and investors should pay attention to these rating changes to make informed investment choices.
- Source of Updates: Comprehensive information on analyst rating changes, including upgrades and downgrades, can be found on our analyst ratings page, providing a thorough market insight.
- Market Impact: Adjustments in analysts' ratings not only affect the performance of individual stocks but may also create fluctuations in overall market sentiment, prompting investors to closely monitor these changes to seize investment opportunities.
See More
